secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001829126-25-005008
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc signs $50M non-binding term sheet with Quazar for UAE clinical platform expansion
--------------------------------------------------------------------------------

- $50M equity investment at $25/share from Quazar Investment; board approved June 30, 2025.
- Formation of NuroMENA Holdings and NuroCure in UAE to run clinical trials for NEO100 and NEO212.
- 70% of funds to buy NTHI common stock at $25/share; 30% for clinical trials and infrastructure.
- Conditions include sub-license from USC Stevens Center, offering docs, and two-year plan within 120 days.
- Partnership leverages Cleveland Clinic Abu Dhabi for trials under US FDA protocols.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625005008/0001829126-25-005008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625005008/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-005008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer